Agenus encouraged by early HerpV results

Lexington, MA-based Agenus reported promising Phase I results of its recombinant therapeutic vaccine HerpV for the treatment of genital herpes in a study published in the journal Vaccine. The developer is planning a Phase II trial of the drug in 2012 to test the vaccine on viral shedding in patients infected with HSV-2. "We are very encouraged by these clinical results as published literature suggest that cellular immunity needs to be stimulated for successful treatment of genital herpes--a physically painful and emotionally debilitating disease that affects one in six adults in the U.S.," noted lead author Anna Wald. Agenus release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.